Regentis Biomaterials Ltd. – Filings and Transcripts

NYSE American: RGNT
Share price (3/10/26): $3.38
Market cap (3/10/26): $17.5 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025 – amended

ended 12/31/25 FY 2025

Prospectuses and Registrations Filter

Prospectus supplement

Free writing prospectus

Initial registration of new securities for foreign issuers – amended

Free writing prospectus

Initial registration of new securities for foreign issuers – amended

Ownership Filter

News Filter

Reports 2025 Financial Results and Provides Business Update

Expands Its European Clinical Site Network to Support Its Commercial and Clinical Programs

Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial

Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S

Regentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method

Proxies

No filings in this category.

Other Filter